Search Result

Pathways Recommended:	MAPK/ERK Pathway
Isoforms Recommended:	p38α

Results for "

p38α MAPK

" in MedChemExpress (MCE) Product Catalog:

By Targets:	p38 MAPK (32) Apoptosis (1) Autophagy (14) Casein Kinase (1) Isotope-Labeled Compounds (1) Raf (1) Reactive Oxygen Species (1) TNF Receptor (2) Wnt (1) β-catenin (1)
By Research Areas:	Cancer (11) Cardiovascular Disease (3) Inflammation/Immunology (24) Metabolic Disease (2) Neurological Disease (5)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Antibodies

Targets Recommended: p38 MAPK MAP4K MNK MAPKAPK2 (MK2)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-18874

p38-α MAPK-IN-1 1 Publications Verification	p38 MAPK Autophagy	Others
p38-α MAPK-IN-1 is an inhibitor of **MAPK14 (p38-α), with IC₅₀** of 2300 nM in EFC displacement assay, and 5500 nM in HTRF assay .

HY-146032

p38-α MAPK-IN-4	p38 MAPK	Neurological Disease Inflammation/Immunology
p38-α MAPK-IN-4 (Compound 69) is a selective **p38α MAPK inhibitor with an IC₅₀** of 1.5 µM. p38-α MAPK-IN-4 rapidly and strongly prevents the development of mechanical allodynia (MA) in vivo .

HY-162364

p38-α MAPK-IN-7	p38 MAPK	Neurological Disease
p38-α MAPK-IN-7 (compound 4) is a *p38α-MAPK* inhibitor with an IC₅₀ value of 98.7 nM. p38-α MAPK-IN-7 protects neuronal cells from dexamethasone-induced ROS production .

HY-147518

p38-α MAPK-IN-5	p38 MAPK	Inflammation/Immunology
p38-α MAPK-IN-5 (compound 4e) is a potent *p38α* inhibitor with IC₅₀s of 0.1 nM, 0.2 nM, 944 nM, 4100 nM for p38α, p38 β, p38γ, p38δ, respectively. p38-α MAPK-IN-5 has anti-inflammatory effect. p38-α MAPK-IN-5 has the potential for asthma and chronic obstructive pulmonary disease (COPD) research .

HY-161293

p38-α MAPK-IN-6

p38 MAPK Cancer

p38-α MAPK-IN-6 (compound 3a) is a p38α mitogen-activated protein kinase inhibitor .

p38-α MAPK-IN-6	p38 MAPK	Cancer
p38-α MAPK-IN-6 (compound 3a) is a *p38α* mitogen-activated protein kinase inhibitor .

HY-145564A

Emprumapimod hydrochloride PF-07265803 hydrochloride	p38 MAPK	Cardiovascular Disease Inflammation/Immunology
Emprumapimod (PF-07265803) hydrochloride is an orally active and selective inhibitor of **p38α MAPK**. Emprumapimod hydrochloride can be used for the research of dilated cardiomyopathy and acute inflammatory pain .

HY-W015445

SD-169	p38 MAPK	Metabolic Disease
SD-169 is an orally active ATP-competitive inhibitor of **p38α MAPK, with an IC₅₀** of 3.2 nM. SD-169 also weakly inhibits p38β MAPK with an IC₅₀ of 122 nM. SD-169 prevents the development and progression of diabetes by inhibiting T cell infiltration and activation .

HY-10401

VX-702 3 Publications Verification	p38 MAPK Autophagy	Inflammation/Immunology
VX-702 is a highly selective inhibitor of **p38α MAPK*, 14-fold higher potency against the p38α* versus p38β .

HY-112401

p38 MAP Kinase Inhibitor IV	p38 MAPK	Inflammation/Immunology
p38 MAP Kinase Inhibitor IV is a highly specific ATP-competitive **p38α MAPK inhibitor with IC₅₀*s of 0.13 and 0.55 μM for p38α* and p38β MAPK, respectively .

HY-108645

AL 8697	p38 MAPK Autophagy	Inflammation/Immunology
AL 8697 is a specific and orally active **p38α MAPK inhibitor with an IC₅₀** of 6 nM. AL 8697 displays 14-fold greater inhibition of p38α compared to p38β (IC₅₀=82 nM), and 300-fold selectivity for p38α over a panel of 91 kinases. Anti-inflammatory activity .

HY-120111

MW-150 MW01-18-150SRM	p38 MAPK Autophagy	Neurological Disease Inflammation/Immunology
MW150 (MW01-18-150SRM) is a selective, CNS penetrant, and orally active inhibitor of **p38α MAPK with a K_i** of 101 nM. MW-150 inhibits the ability of the endogenous p38α MAPK to phosphorylate an endogenous substrate MK2 in activated glia .

HY-145564

Emprumapimod PF-07265803	p38 MAPK	Cardiovascular Disease Inflammation/Immunology
Emprumapimod (PF-07265803) is a potent, orally active and selective inhibitor of **p38α MAPK** directly inhibits LPS-induced IL-6 production from RPMI-8226 cell (IC₅₀=100 pM). Emprumapimod can be used for the research of dilated cardiomyopathy and acute inflammatory pain .

HY-131335

p38α inhibitor 2	p38 MAPK	Inflammation/Immunology
p38α inhibitor 2 is a highly potent and selective **p38α MAPK** inhibitor, with a pIC₅₀ of 9.6. p38α inhibitor 2 inhibits the hERG ion channel (IC₅₀=27 μM) and shows a promising selectivity profile when tested in a panel of 51 other protein kinases (<30% inhibition at 10 μM concentration) and a panel of 141 other biological targets .

HY-120111A

MW-150 hydrochloride MW01-18-150SRM hydrochloride	p38 MAPK Autophagy	Neurological Disease Inflammation/Immunology
MW-150 hydrochloride (MW01-18-150SRM hydrochloride) is a selective, CNS penetrant, and orally active inhibitor of **p38α MAPK with a K_i** of 101 nM. MW-150 hydrochloride (MW01-18-150SRM hydrochloride) inhibits the ability of the endogenous p38α MAPK to phosphorylate an endogenous substrate MK2 in activated glia .

HY-144697

p38 MAPK-IN-3	p38 MAPK Apoptosis Reactive Oxygen Species	Cancer
p38 MAPK-IN-3 (Compound 2c) is a **p38α MAPK** inhibitor. p38 MAPK-IN-3 has antitumor activities and induces apoptosis and ROS .

HY-120111B

MW-150 dihydrochloride dihydrate MW01-18-150SRM dihydrochloride dihydrate	p38 MAPK Autophagy	Neurological Disease Inflammation/Immunology
MW-150 dihydrochloride dihydrate (MW01-18-150SRM dihydrochloride dihydrate) is a selective, CNS penetrant, and orally active inhibitor of **p38α MAPK with a K_i** of 101 nM. MW-150 dihydrochloride dihydrate (MW01-18-150SRM dihydrochloride dihydrate) inhibits the ability of the endogenous p38α MAPK to phosphorylate an endogenous substrate MK2 in activated glia .

HY-110398

5,6,7-Trimethoxyflavone Baicalein trimethyl ether	p38 MAPK	Inflammation/Immunology Cancer
5,6,7-Trimethoxyflavone is a novel **p38-α MAPK** inhibitor with an anti-inflammatory effect. 5,6,7-Trimethoxyflavone is isolated from several plants including Zeyhera tuberculosa, Callicarpa japonica, and Kickxia lanigera .

HY-10402

Losmapimod 10+ Cited Publications GSK-AHAB; GW856553X; SB856553	p38 MAPK Autophagy	Inflammation/Immunology Cancer
Losmapimod (GSK-AHAB) is a selective, potent, and orally active p38 MAPK inhibitor with pK_is of 8.1 and 7.6 for p38α and p38β, respectively .

HY-135674

SR-318	p38 MAPK TNF Receptor	Inflammation/Immunology Cancer
SR-318 is a potent and highly selective p38 MAPK inhibitor with IC₅₀s of 5 nM, 32 nM and 6.11 μM for p38α, p38β and p38α/β, respectively. SR-318 potently inhibits the TNF-α release in whole blood with an IC₅₀ of 283 nM. SR-318 has anti-cancer and anti-inflammatory activity .

HY-11068

SB 239063 Maximum Cited Publications 26 Publications Verification	p38 MAPK Autophagy	Inflammation/Immunology
SB 239063 is a potent, selective and orally active p38 MAPK inhibitor, exhibits an IC₅₀ of 44 nM for recombinant purified human p38α, with equipotent inhibitory activity against p38α and p38β. SB 239063 has no effect on p38γ or p38δ. With anti-asthma activity and also be used to enhance memory which is impaired due to aging or medical conditions, such as, AD .

HY-14305A

BMS-582949 hydrochloride 1 Publications Verification	p38 MAPK Autophagy	Inflammation/Immunology
BMS-582949 hydrochloride is an orally active and highly selective **p38α MAPK inhibitor, with an IC₅₀** of 13 nM. BMS-582949 hydrochloride displays a significantly improved pharmacokinetic profile and is effective in inflammatory disease .

HY-16782

Pexmetinib 1 Publications Verification ARRY-614	p38 MAPK Autophagy	Cancer
Pexmetinib is a potent Tie-2 and p38 MAPK dual inhibitor, with IC₅₀s of 1 nM, 35 nM and 26 nM for Tie-2, p38α and p38β, respectively, and can be used in the research of acute myeloid leukemia.

HY-N2375

L-Quebrachitol	Wnt β-catenin	Metabolic Disease
L-Quebrachitol is a natural product isolated from many plants, promotes osteoblastogenesis by uppregulation of BMP-2, runt-related transcription factor-2 (Runx2), *MAPK* (ERK, JNK, p38α), and Wnt/β-catenin signaling pathway .

HY-18759

BMS-751324	p38 MAPK TNF Receptor	Inflammation/Immunology
BMS-751324 is a **p38α MAPK inhibitor. BMS-751324 equips a precursor of carbamyl-methyl linkage, containing esters and phosphate functional groups derived from hydroxyphenylacetic acid (HPA). BMS-751324 effectively inhibits foot swelling and LPS-induced TNFα** production in an arthritic rat model .

HY-10406

Talmapimod 3 Publications Verification SCIO-469	p38 MAPK	Cancer
Talmapimod (SCIO-469) is an orally active, selective, and ATP-competitive *p38α* inhibitor with an IC₅₀ of 9 nM. Talmapimod shows about 10-fold selectivity over p38β, and at least 2000-fold selectivity over a panel of 20 other kinases, including other MAPKs .

HY-10406A

Talmapimod hydrochloride SCIO-469 hydrochloride	p38 MAPK	Cancer
Talmapimod (SCIO-469) hydrochloride is an orally active, selective, and ATP-competitive *p38α* inhibitor with an IC₅₀ of 9 nM. Talmapimod hydrochloride shows about 10-fold selectivity over p38β, and at least 2000-fold selectivity over a panel of 20 other kinases, including other MAPKs .

HY-13241A

Ralimetinib LY2228820	p38 MAPK Autophagy	Inflammation/Immunology Cancer
Ralimetinib (LY2228820) is a potent and selective, ATP-competitive inhibitor of *p38 MAPK* α/β, with IC₅₀*s of 5.3 and 3.2 nM, respectively. Ralimetinib (LY2228820) selectively inhibits phosphorylation of MK2 (Thr334), with no effect on phosphorylation of p38α* MAPK, JNK, ERK1/2, c-Jun, ATF2, or c-Myc .

HY-15505

RWJ-67657 JNJ 3026582	p38 MAPK	Cardiovascular Disease Inflammation/Immunology Cancer
RWJ-67657 (JNJ 3026582) is an orally active and selective *p38α* and p38β MAPK inhibitor with IC₅₀s of 1 and 11 μM, respectively. RWJ-67657 displays no activity at p38γ and p38δ, and exhibits cardio protective effect. Anti-inflammatory and anti-tumor activity .

HY-10320

Doramapimod 20+ Cited Publications BIRB 796	p38 MAPK Raf Autophagy	Inflammation/Immunology Cancer
Doramapimod (BIRB 796) is an orally active, highly potent p38 MAPK inhibitor, which has an IC₅₀ for p38α=38 nM, for p38β=65 nM, for p38γ=200 nM, and for p38δ=520 nM. Doramapimod has picomolar affinity for p38 kinase (K_d=0.1 nM). Doramapimod also inhibits B-Raf with an IC₅₀ of 83 nM .

HY-10405

Pamapimod Ro4402257; R1503	p38 MAPK Autophagy	Inflammation/Immunology
Pamapimod (Ro4402257) is a potent, selective and orally active p38 MAPK inhibitor with IC₅₀s of 14 nM and 480 nM and K_is of 1.3 nM and 120 nM for *p38α* and p38β, respectively. Pamapimod has no activity against p38δ or p38γ isoforms. Pamapimod has the potential for rheumatoid arthritis and other autoimmune diseases treatment .

HY-10456

TAK-715 10+ Cited Publications	p38 MAPK Casein Kinase	Inflammation/Immunology
TAK-715 is an orally active and potent p38 MAPK inhibitor with IC₅₀s of 7.1 nM, 200 nM for p38α and p38β, respectively. TAK-715 inhibits casein kinase I (CK1δ/ε) to regulate activation of Wnt/β-catenin signaling. TAK-715 shows good significant efficacy in a rat arthritis model .

HY-18862

PF-03715455
PF-03715455 is a potent inhaled p38 MAPK inhibitor. PF-03715455 shows some selectivity for p38α over p38β with respective IC₅₀ values of 0.88 and 23 nM. PF-03715455 potently inhibits LPS-induced TNFα production in human whole blood (IC₅₀=1.7 nM). PF-03715455 has potential for the treatment of COPD (chronic obstructive pulmonary disease) .

HY-10405S

Pamapimod-d4	Isotope-Labeled Compounds p38 MAPK Autophagy	Inflammation/Immunology
Pamapimod-d₄ (Ro4402257-d4) is the deuterium labeled Pamapimod. Pamapimod (Ro4402257) is a potent, selective and orally active p38 MAPK inhibitor with IC50s of 14 nM and 480 nM and Kis of 1.3 nM and 120 nM for p38α and p38β, respectively. Pamapimod has no activity against p38δ or p38γ isoforms. Pamapimod has the potential for rheumatoid arthritis and other autoimmune diseases treatment[1][2].

HY-10403A

(aS)-PH-797804	p38 MAPK	Inflammation/Immunology
(aS)-PH-797804 is a selective p38 MAPK inhibitor with IC₅₀ values for p38 α /β of 26 nM and 102 nM, respectively. (aS)-PH-797804 has anti-inflammatory activity .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-110398

5,6,7-Trimethoxyflavone Baicalein trimethyl ether	Structural Classification Flavonoids Classification of Application Fields Flavones Verbenaceae Plants Bignoniaceae Oroxylum indicum (Linn.) Bentham ex Kurz Inflammation/Immunology Disease Research Fields Callicarpa japonica Thunb. Cancer	p38 MAPK
5,6,7-Trimethoxyflavone is a novel **p38-α MAPK** inhibitor with an anti-inflammatory effect. 5,6,7-Trimethoxyflavone is isolated from several plants including Zeyhera tuberculosa, Callicarpa japonica, and Kickxia lanigera .

HY-N2375

L-Quebrachitol	Natural Products other families Classification of Application Fields Source classification Metabolic Disease Plants Disease Research Fields	Wnt β-catenin
L-Quebrachitol is a natural product isolated from many plants, promotes osteoblastogenesis by uppregulation of BMP-2, runt-related transcription factor-2 (Runx2), *MAPK* (ERK, JNK, p38α), and Wnt/β-catenin signaling pathway .

Cat. No.	Product Name	Chemical Structure

HY-10405S

Pamapimod-d4
Pamapimod-d₄ (Ro4402257-d4) is the deuterium labeled Pamapimod. Pamapimod (Ro4402257) is a potent, selective and orally active p38 MAPK inhibitor with IC50s of 14 nM and 480 nM and Kis of 1.3 nM and 120 nM for p38α and p38β, respectively. Pamapimod has no activity against p38δ or p38γ isoforms. Pamapimod has the potential for rheumatoid arthritis and other autoimmune diseases treatment[1][2].

Pamapimod-d4

Pamapimod-d₄ (Ro4402257-d4) is the deuterium labeled Pamapimod. Pamapimod (Ro4402257) is a potent, selective and orally active p38 MAPK inhibitor with IC50s of 14 nM and 480 nM and Kis of 1.3 nM and 120 nM for p38α and p38β, respectively. Pamapimod has no activity against p38δ or p38γ isoforms. Pamapimod has the potential for rheumatoid arthritis and other autoimmune diseases treatment[1][2].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks